XNASATXI
Market cap3mUSD
Dec 24, Last price
1.72USD
1D
-4.44%
1Q
-23.21%
IPO
-99.98%
Name
Avenue Therapeutics Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
-27.03%
Rev. gr., 5y
%
Revenues
0k
Net income
-10m
L
CFO
-9m
L+24.42%
Earnings
Mar 17, 2025
Profile
Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain. The company was incorporated in 2015 and is based in New York, New York.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | 14,540 | 8,043 | 3,738 | ||||||
Unusual Expense (Income) | |||||||||
NOPBT | (14,540) | (8,043) | (3,738) | ||||||
NOPBT Margin | |||||||||
Operating Taxes | (5,651) | (7) | |||||||
Tax Rate | |||||||||
NOPAT | (14,540) | (2,392) | (3,731) | ||||||
Net income | (10,377) -606.69% | 2,048 -154.99% | (3,724) -26.82% | ||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 7,525 | 10,901 | 5,044 | ||||||
BB yield | -441.29% | -5.73% | -0.44% | ||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | 949 | ||||||||
Net debt | (1,783) | (6,708) | (3,763) | ||||||
| Cash flow | |||||||||
Cash from operating activities | (9,451) | (7,596) | (3,750) | ||||||
CAPEX | |||||||||
Cash from investing activities | (3,000) | ||||||||
Cash from financing activities | 7,526 | 10,541 | 4,381 | ||||||
FCF | (14,540) | (2,392) | (3,731) | ||||||
| Balance | |||||||||
Cash | 1,783 | 6,708 | 3,763 | ||||||
Long term investments | |||||||||
Excess cash | 1,783 | 6,708 | 3,763 | ||||||
Stockholders' equity | (91,853) | (81,190) | (76,997) | ||||||
Invested Capital | 92,507 | 84,456 | 80,448 | ||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | 141 | 2,185 | 1,133 | ||||||
Price | 12.08 -86.12% | 87.00 -91.48% | 1,021.50 -84.74% | ||||||
Market cap | 1,705 -99.10% | 190,109 -83.58% | 1,157,533 -84.29% | ||||||
EV | (1,006) | 182,762 | 1,153,770 | ||||||
EBITDA | (14,540) | (8,043) | (3,738) | ||||||
EV/EBITDA | 0.07 | ||||||||
Interest | 1,160 | ||||||||
Interest/NOPBT | |||||||||